Armata Pharmaceuticals, Inc.

AMEX:ARMP

Biotechnology

Healthcare
$3.17 -0.28%

-$0.02 today

Market cap
$117.90M
Beta
1.22
P/E (TTM)
-0.9
EPS (TTM)
-$7.74
52W Low $1.81High $16.34

Volume 0.09M

Average 0.07M

ARMP Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Armata Pharmaceuticals, Inc.AMEX: ARMP

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation growth accelerates

Q1 FY2026 stock-based compensation of $1.08M rose 37.6% year over year, ahead of the -7.5% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 70.1% from the prior quarter. Over 3 fiscal years it compounded at -5.6% a year.

Context

  • Stock-based compensation amounted to 53.2% of revenue in FY2025, down 2.7 pp from a year earlier.
  • Stock-based compensation increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +37.6% holds above the trailing-twelve-month pace of -7.5%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.08M+70.1% QoQ
Last fiscal yearDec 2025
$2.61M-9.8% YoY
LTMMar 2026
$2.9M-7.5% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+37.6%——
1 year-9.8%——
3-year CAGR-5.6%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
2.61M USD
Year-over-year change
-9.8%
4-year CAGR
-2.4%

Stock-Based Compensation vs competitors

How ARMP compares with its peers on the latest reported figures

  • ARMP's LTM Mar 2026 stock-based compensation of $2.9M is the smallest of the 2 companies compared; the peer median is $3.88M.
  • Its year-over-year change of -7.5% is the highest of 2, against a peer median of -47.0%.
  • Stock-based compensation amounts to 98.2% of revenue for ARMP, versus a peer median of 7.1%.
ARMP Competitors Peer median
Stock-Based Compensation for ARMP and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SPROSpero Therapeutics, Inc.LTM Mar 2026$3.88M -47.0%-22.0%7.1%
ARMPArmata Pharmaceuticals, Inc.LTM Mar 2026$2.9M -7.5%-5.6%98.2%
Peer median (excluding ARMP) $3.88M-47.0%-22.0%7.1%

Competitors are the stored peer set for ARMP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(23.16M)(36.92M)(69.05M)(18.92M)(173.8M)
Depreciation & Amortization1.17M892K972K1.33M1.53M
Deferred Income Tax00000
Stock-Based Compensation2.88M3.11M938K2.89M2.61M
Change in Working Capital(3.22M)439K(9.65M)(2.1M)(1.41M)
Accounts Receivables(2.43M)1.05M000
Inventory00000
Accounts Payables184K3.67M39K(3.76M)(334K)
Other Working Capital(979K)(4.28M)(9.69M)1.66M(1.08M)
Other Non-Cash Items(1.25M)029.36M(20.75M)145.31M
Operating Cash Flow(23.58M)(32.48M)(47.42M)(37.55M)(25.76M)
Capital Expenditures(1.3M)(2.21M)(8.14M)(1.88M)(542K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities0010K00
Investing Cash Flow(1.3M)(2.21M)(8.13M)(1.88M)(542K)
Debt Repayment0054.03M34.89M25M
Common Stock Issued26.32M44.52M5K130K658K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(801K)(500K)(43K)(61K)(46K)
Financing Cash Flow25.52M44.02M53.99M34.96M25.61M
Effect of Forex Changes0(4.76M)000
Net Change in Cash639K4.56M(1.57M)(4.47M)(693K)
Free Cash Flow(24.88M)(34.69M)(55.57M)(39.43M)(26.31M)

Armata Pharmaceuticals, Inc.

AMEX:ARMP

Intrinsic Alpha fair value

Locked

Current Price

$3.17

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.